Company
University from which Arovella licensed its invariant natural killer T cell platform
London, OS
Every investor coverage indicates participated in a round Imperial College London raised.
Companies Imperial College London acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Imperial College London. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.